Baricitinib-induced paradoxical psoriasis
- 1 August 2020
- journal article
- letter
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (8), E391-E393
- https://doi.org/10.1111/jdv.16293
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- IκBζ is a key transcriptional regulator of IL-36-driven psoriasis-related gene expression in keratinocytesProceedings of the National Academy of Sciences of the United States of America, 2018
- TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasisNature Communications, 2018
- Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulnessTherapeutic Advances in Musculoskeletal Disease, 2017
- IL-8 promotes inflammatory mediators and stimulates activation of p38 MAPK/ERK-NF-κB pathway and reduction of JNK in HNSCCOncotarget, 2017
- Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overviewRMD Open, 2016
- IκBζ is a key driver in the development of psoriasisProceedings of the National Academy of Sciences of the United States of America, 2015
- PsoriasisAnnual review of pathology, 2012